Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Papadopoulos Kyriakos P.; Siegel David S.; Vesole David H.; Lee Peter; Rosen Steven T.; Zojwalla Naseem; Holahan Joseph R.; Lee Susan; Wang Zhengping; Badros Ashraf

首页> 外文期刊>Journal of Clinical Oncology >Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

【24h】

Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

机译：复发和/或难治性多发性骨髓瘤患者单用卡非佐米或与小剂量地塞米松联用30分钟输注的I期研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2015年第7期|共11页
作者
Papadopoulos Kyriakos P.; Siegel David S.; Vesole David H.; Lee Peter; Rosen Steven T.; Zojwalla Naseem; Holahan Joseph R.; Lee Susan; Wang Zhengping; Badros Ashraf;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma [J] . Papadopoulos Kyriakos P., Siegel David S., Vesole David H., Journal of Clinical Oncology . 2015,第7期

机译：复发和/或难治性多发性骨髓瘤患者单用卡非佐米或与小剂量地塞米松联用30分钟输注的I期研究
2. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma [J] . JagannathS., VijR., StewartA.K., Clinical lymphoma, myeloma & leukemia . 2012,第5期

机译：低剂量单药卡非佐米在复发性和难治性多发性骨髓瘤患者中的开放标签式单臂试验II期研究（PX-171-003-A0）
3. Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma [J] . Mateos Maria-Victoria, Granell Miguel, Oriol Albert, British Journal of Haematology . 2016,第3期

机译：厄洛珠单抗联合沙利度胺和小剂量地塞米松：对复发/难治性多发性骨髓瘤患者的2期单臂安全性研究
4. THALIDOMIDE PLUS INTERMEDIATE-DOSE DEXAMETHASONE IN REFRACTORY/RELAPSED AL PATIENTS [C] . Giovanni Palladini, Vittorio PerfettF, Stefano Perlini, International Symposium on Amyloidosis . 2005

机译：沙利度胺加上难治性/复发患者中的中间剂量地塞米松
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. An open-label single-arm phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma [O] . Ravi Vij, Michael Wang, Jonathan L. Kaufman, -1

机译：开放性单臂2期（PX-171-004）单药卡非佐米治疗未接受硼替佐米的复发和/或难治性多发性骨髓瘤患者的单药研究
7. Elotuzumab in combination with thalidomide and low-dose dexamethasone:a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma [O] . Mateos Maria-Victoria, Granell Miguel, Oriol Albert, 2016

机译：厄洛珠单抗联合沙利度胺和小剂量地塞米松：复发/难治性多发性骨髓瘤患者的2期单臂安全性研究

Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

摘要

著录项

相似文献

相关主题

期刊订阅